Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
    Meeting Abstract

    Gruenwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suarez Rodriguez, C.; Negrier, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
    Meeting Abstract

    Pal, S. K.; Powles, T. B.; Kanesvaran, R.; Lee, C. H.; Liu, M.; Wang, Z.; Bhatt, A.; Patel, P.; Suarez Rodriguez, C.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
    Meeting Abstract

    Kasper, B.; Gounder, M.; Chugh, R.; Agulnik, M.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; Gordon, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39)
    Meeting Abstract

    Basch, E.; Schrag, D.; Jansen, J.; Ginos, B.; Spears, P. A.; Jonsson, M.; Carr, P.; Deal, A. M.; Thanarajasingam, G.; Reeve, B. B.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Chi, P.; Shen, L.; Li, J.; Zhang, J.; Hu, K.; Zhang, L.; Xu, Y.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Assessing PSA
    Meeting Abstract

    Halabi, S.; Roy, A.; Guo, S.; Rydzewska, L.; Godolphin, P. J.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Carducci, M. A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
    Meeting Abstract

    Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
    Meeting Abstract

    Voss, M. H.; Garmezy, B.; Kim, S. H.; Rey, J. P. M.; Mansinho, A. B.; Rodriguez-Vida, A.; Oliveira, J.; van Dongen, M.; Medina Rodríguez, L.; Negrier, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
    Meeting Abstract

    Shah, N. J.; Campbell, M. T.; Mao, S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H.; Keshava-Prasad, H.; Hoimes, C. J.; Hussain, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W.; Danila, D.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P.; Armstrong, A. J.; Pook, D.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save